Merche Gironella (@mgironella) header
Merche Gironella (@mgironella) profile picture
Barcelona
Joined October 2013
Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)Photo by Merche Gironella (@mgironella)
La simulació clínica permet entrenar el maneig de tractaments complexos. Hem fet una formació per especialistes en hematologia sobre el maneig del pacient amb mieloma múltiple en recaiguda, treballant diferents situacions clíniques i les possibles complicacions dels tractaments.
1
5
242
Merche Gironella retweeted
Just in: Good news for the myeloma field. FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy. Note: Always use Tec-Dara with monthly IVIG. It’s not optional. That was fast! And this is unprecedented curve is why.
7
89
9
298
26,684
Merche Gironella retweeted
Just out in @NEJM Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos Link: nejm.org/doi/full/10.1056/NE… More in thread
2
27
6
80
32,793
Merche Gironella retweeted
Ampliamos equipo! Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪 Te apuntas? (Contactar [email protected])
16
24
1,567
S'ha fet el curs sobre Mieloma múltiple, centrat en la millora de l’atenció a pacients en recaiguda. 🎯 Objectius: identificar necessitats, avaluar alternatives terapèutiques, detectar toxicitats i prevenir complicacions. Enhorabona per la feina feta! 👏
1
3
97
Congratulations InmaFernandez for the poster presented at #IMS @Hemato_Vhebron
1
8
256
Andromeda data after 5 years, very reassuring! #EHA2025
11
1
43
4,272
Merche Gironella retweeted
CONGRESS | #EHA2025 | Evangelos Terpos @uoaofficial shares the latest update to the EHA-EMN clinical practice guidelines for diagnosis, treatment, and follow-up. Key updates include new guidelines on defining high-risk disease, examinations upon diagnosis, monitoring for SMM, quadruplet regimens in NDMM, targeted therapies in early relapse and sequencing immunotherapies. Follow our live feed for more updates: loom.ly/hq6n5HU #mmsm #myeloma #MedEd #MedNews
1
21
2
44
5,297
Merche Gironella retweeted
CONGRESS | #ASCO25 | Suzanne Trudel @pmcancercentre discusses MRD negativity from the DREAMM-8 trial of belamaf plus Pd vs PVd for R/R #MultipleMyeloma. BPd was associated with increased rates of CR-based MRD negativity and MRD negativity was associated with PFS and OS benefits across key subgroups. Follow our live feed for more updates: loom.ly/s_RkmMc #mmsm #myeloma #MedicalCongress
2
11
796
Merche Gironella retweeted
Presented at #ASCO25: In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results: nej.md/4mkaecR @ASCO
2
38
5
106
32,352
Merche Gironella retweeted
The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! ⁦@JCO_ASCO⁩ ⁦@TheIACH⁩ ⁦@COMyCongress⁩
1
9
25
1,858
Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly reduced CRS, no ICANS seen. #ASCO25
2
31
90
9,257
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance @iStopMM @JAMAOnc #mmsm jamanetwork.com/journals/jam… Important data coming to support need for new ranges of normal free light chains based on eGFR👇
1
43
91
5,924
Macroglobulinemia de Waldeström- Tratamiento Selección del Esquema según los síntomas del pacientes y los posibles #EAs de los medicamentos @Fer_martinmoro @HematoRYC en #AgoraH25 #HematoEnRed @sehh_es @SEHHJoven
19
48
3,330
Merche Gironella retweeted
Brief Report: CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma (CARTITUDE-4 trial) nej.md/4gA6G27 #Hematology
10
32
10,728
Merche Gironella retweeted
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 @thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.1056/NE… Slides in thread
17
125
14
348
110,599
Merche Gironella retweeted
Approach to MGUS + neuropathy - Rule out more common causes of peripheral neuropathy - Rule out MM/WM/AL amyloidosis - Consider MGUS associated neuropathies: type 1 cryogenic, CIDP mimickers (DADS-M, MADSAM, POEMS, CANOMAD)
2
96
1
310
34,890